“With my background in developing medical policies and making coverage decisions as the CMO for Blue Shield of California and as a Medicare Part B Medical Director, I have found that an ongoing evidence development plan is one of the key elements in achieving widespread coverage, appropriate reimbursement, and long term success. At Quorum we work with companies with to develop a comprehensive evidence plan to optimize coverage and reimbursement and thus satisfy payers while also meeting short-term objectives.”
Dr. Wade Aubry is Quorum’s in-house Medical Director, where he works with clients on evidence development and reimbursement strategy to help achieve widespread adoption and long term coverage and payment for their products, including medical devices, diagnostics, biotechnology, pharmaceuticals, and digital health. He has extensive experience in healthcare technology assessment and coverage decisions in both regional and national BCBS Plans and in Medicare. Trained in internal medicine and endocrinology at Cedars-Sinai Medical Center, Dr. Aubry is a graduate of Stanford (BS) and UCLA (MD), practiced medicine in San Francisco, and served as Chief of Staff at Saint Francis Memorial Hospital and as Associate Clinical Professor of Medicine at UCSF, where he is also Core Faculty at the Philip R. Lee Institute for Health Policy Studies.
For several years, Dr. Aubry served as Senior Vice President and Chief Medical Officer for Blue Shield of California and as Medicare Part B Carrier Medical Director, where he was active in developing coverage policies and making coverage decisions. He also served as Chairman of the national BCBSA TEC Medical Advisory Committee for 6 years and as a member of the CMS Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) for 6 years. Other positions include service on several national medical advisory panels for AHRQ, NIH, IOM, NCQA, and ACRIN (American College of Radiology Imaging Network). He has served as Vice President of the Lewin Group, Senior Advisor for (HealthTech), Senior Clinical and Policy Advisory for CMTP, and Senior Medical Advisor for CTAF.
At UCSF, he teaches in health policy and conducts research on health insurance mandates. He is also a member of the UCSF Healthcare Technology Assessment Program Committee, which considers new technology adoption in hospitals. Dr. Aubry has published numerous articles on medical technology and managed care, and he is a co-author of a comprehensive case study on the rise and fall of a controversial breast cancer treatment entitled False Hope: Bone Marrow Transplantation for Breast Cancer (Oxford University Press, 2007).
Executive Education in Finance, Stanford Graduate School of Business
Executive Education in General Management, Kellogg School of Management, Northwestern
Fellowship, Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center
Residency, Internal Medicine, Cedars-Sinai Medical Center
MD, David Geffen School of Medicine at UCLA
BS, Stanford University, Elected to Phi Beta Kappa
Technology Assessment, Coverage Decisions, Quality Measurement, Clinical Decision Making